



























Name	Relative Retention Time	Acceptance Criteria, NMT (%)
4-Epiminocycline <sup>a</sup>	0.38	4.0
Desmethyl minocycline <sup>b,c</sup>	0.46	—
Sancycline <sup>b,d</sup>	0.68	—
5a,6-Anhydrominocycline <sup>b,e</sup>	0.81	—
Hydroxymethylminocycline <sup>b,f</sup>	0.92	—
Minocycline	1.0	—
Any individual unspecified degradation product	—	0.2
Total degradation products <sup>g</sup>	—	2.0

<sup>a</sup> (4*R*,4*aS*,5*aR*,12*aS*)-4,7-Bis(dimethylamino)-3,10,12,12*a*-tetrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide.

<sup>b</sup> Process impurities are controlled in the drug substance and are not to be reported here. They are not included in total degradation products.

<sup>c</sup> (4*S*,4*aS*,5*aR*,12*aS*)-4-Dimethylamino-3,10,12,12*a*-tetrahydroxy-7-methylamino-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide.

<sup>d</sup> 6-Demethyl-6-deoxytetracycline; (4*S*,4*aS*,5*aR*,12*aS*)-4-Dimethylamino-3,10,12,12*a*-tetrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide.

<sup>e</sup> (4*S*,4*aS*,12*aS*)-4,7-Bis(dimethylamino)-3,10,11,12*a*-tetrahydroxy-1,12-dioxo-1,4,4*a*,5,12,12*a*-hexahydrotetracene-2-carboxamide.

<sup>f</sup> (4*S*,4*aS*,5*aR*,12*aS*)-4,7-Bis(dimethylamino)-3,10,12,12*a*-tetrahydroxy-*N*-(hydroxymethyl)-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide.

<sup>g</sup> Total degradation products does not include 4-epiminocycline.

## ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Store in tightly closed containers at controlled room temperature.
- **LABELING:** When more than one *Dissolution* test is given, the labeling states the *Dissolution* test used only if *Test 1* is not used.
- **USP REFERENCE STANDARDS** (11)  
[USP Minocycline Hydrochloride RS](#)

### Page Information:

Not Applicable

### DocID:

© 2020 The United States Pharmacopeial Convention *All Rights Reserved*.